Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer\'s Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Epistemonikos ID: eaa2cd0195f80746d0e4edeb0ff48e6fc1bd842a
First added on: May 22, 2024